Fig. 5From: Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomesGraphs showing change in mean quality of life scores (PHQ9, HIT-6, and PDI) before and after commencing erenumab. Three months of baseline data (month 0, 1, 2) is followed by 9 months of post-treatment data (month 3–11). Error bars represent standard error of the meanBack to article page